1269P - Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
- Resource Type
- Abstract
- Source
- In
Annals of Oncology October 2019 30 Supplement 5:v516-v516 - Subject
- Language
- ISSN
- 0923-7534